Cardiac allograft transplantation

Fairchild, R. L., VanBuskirk, A. M., Kondo, T., Wakely, M. E., and Orosz, C. G. (1997) Expression of chemokine genes during rejection and long-term acceptance of cardiac allografts. Transplantation 63,1807-1812. 

Oshima, K., Sen, L., Cui, G. G., Tung, X, Sacks, B. M., Arellano-Kruse, A., and Laks, H. 2002. Localized interleukin-10 gene transfer Induces apoptosis of aUoreactive T cells via Fas/FasL pathway, improves function, and prolongs survival of cardiac allograft. Transplantation, 73,1019-1026. 

Highly experienced in neonatal heart transplantation is the Loma Linda group. They started their program of neonatal cardiac allograft transplantation in 1985 after the spectacular baboon heart xenotransplantation in Baby Fae in 1984 (Bailey et al. 1985). 

Yun JJ, Fischbein MP, Laks H, et al. Rantes production during development of cardiac allograft vasculopathy. Transplantation 2001 71(11) 1649-1656. 

Bishop DK, Li W, Chan SY, Ensley RD, et al. 1994. Helper T lymphocytes unresponsiveness to cardiac allografts following transient depletion of CD4-positive cells. Implications for cellular and humoral responses. Transplantation. 58 576-584. 

Schofield RS, Hill JA, McGinn CJ, Aranda JM. Hormone therapy in men and risk of cardiac allograft rejection. J Heart Lung Transplant 2002 21(4) 493-5. 

Yangs, Z. D., Rostami, S., Koeberlein, B., Barker, C. F. and Naji, A. (1999). Cardiac allograft tolerance induced by intra-arterial infusion of recombinant adenoviral CTLA4Ig. Transplantation 67, 1517-1523. 

Poston RS, Mann MJ, Hoyt EG, Ennen M, Dzau VJ, Robbins RC. Antisense oligodeoxynucleotides prevent acute cardiac allograft rejection via a novel, non-toxic, highly efficient transfection method. Transplantation 1999 68 825-832. 

Prolongs the survival rate of transplanted hearts using a model of cardiac allograft rejection in mice [142]... 

Beranek JT. Further evidence of cardiomyocyte apoptosis in humoral (microvascular) rejection of human cardiac allografts. J Heart Lung Transplant 2004 23 378-379. 

Greenberg A, Thompson ME, Griffith BJ, Hardesty RL, Kormos RL, el-Shahawy MA, Janosky JE, Puschett JB. Cyclosporine nephrotoxicity in cardiac allograft patients— a seven-year follow-up. Transplantation 1990 50(4) 589-93. 

Kuo PC, Lulkart H, Busse-Henry S, Hunt SA, Valantine HA, Stinson EB, Oyer PE, Scandling JD, Alfrey EJ, Dafoe DC. Clinical outcome of Interval cadaveric renal transplantation In cardiac allograft recipients. Clin Transplant 1995 9 92-97. 

Piazza, A., Torlone, N., Valeri, M., Poggi, E., Adorno, D., and Casciani, C. U. Flow cytometry crossmatching in donor/recipient selection. Transplant. Proc. 23, 2681-2682 (1991). Raffoux, C., Mayor, V., Cabrol, C., Busson, M., Hors, J., and Colombani, J. The influence of HLA matching in cardiac allograft recipients in a single center. Transplant. Proc. 19, 3559-3560 (1987). 

Chueh et al. have demonstrated that curcumin enhances the immunosuppressive activity of cyclosporine in rat cardiac allografts and in mixed lymphocyte reactions. Their study demonstrated for the first time the effectiveness of curcumin as a novel adjuvant immunosuppressant with cyclosporine both in vivo and in vitro. The immunosuppressive effects of curcumin were studied in rat heterotrophic cardiac transplant models, using Brown-Norway hearts transplanted to WKY hosts. In the Brown-Norway-to-WKY model, curcumin alone significantly increased the mean survival time, to 20.5 to 24.5 days as compared with 9.1 days in nontreated controls. The combination of curcumin and subtherapeutic doses of cyclosporine further prolonged the mean survival time to 28.5 to... 

Renal transplant rejection Influenza A L. major Cardiac allograft rejection Coronavirus... 

Kapoor A, Morita K, Engeman TM, et al. Early expression of interferon-gamma inducible protein 10 and monokine induced by interferon-gamma in cardiac allografts is mediated by CD8-I- T cells. Transplantation 2000 69 1147-1155. 

Jiang J, Arp J, Kubelik D et al. Induction of indefinite cardiac allograft siuvival correlates with toll-like receptor 2 and 4 downregulation after serine protease inhibitor-1 (serp-1) treatment. Transplantation 2007 84 1158-1167. 

---